Simon Leeson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simon Leeson has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Charles W.E. Redman
Consultant Gynaecologist, Department of Obstetrics and Gynaecology, University Hospital of North Staffordshire, Stoke-on-Trent ST4 6QG, UK
2 shared publicationsChristine Bergeron
Département Anatomocytopathologie, 95066, Paris, France
2 shared publicationsPekka Nieminen
Department of Obstetrics and Gynecology, Helsinki University Hospital, Finland and University of Helsinki, 00029, HUS, Finland
2 shared publicationsA. Alalade
Department of Obstetrics and Gynaecology, Betsi Cadwaladr University Health Board
1 shared publicationA. Ciavattini
Department of Woman's Health Sciences, Gynecologic Section, Polytechnic University of Marche, Ancona, Italy
1 shared publicationA. Pedro
Department of Obstetrics and Gynaecology, Cuf Sintra Hospital, Sintra, Portugal
1 shared publication
Latest Publications
- Open Access
Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study
We investigated URS and impact on survival in whole patient cohorts with AOC treated within gynaecological cancer centres that participated in the previously presented SOCQER 2 study. National cancer registry datasets were used to identify FIGO Stage 3,4 and unknown stage patients from 11 cancer centres that had previously participated in the SOCQER2 study. Patient outcomes’ association with surgical ethos were evaluated using logistic regression and Cox proportional hazards. Centres were classified into three groups based on their surgical complexity scores (SCS); those practicing mainly low complexity, (5/11 centres with >70% low SCS procedures, 759 patients), mainly intermediate (3/11, 35–50% low SCS, 356 patients), or mainly high complexity surgery (3/11, >35% high SCS, 356 patients). Surgery rates were 43.2% vs. 58.4% vs. 60.9%. across mainly low, intermediate and high SCS centres, respectively, p < 0.001. Combined surgery and chemotherapy rates were 39.2% vs. 51.8% vs. 38.3% p < 0.000 across mainly low, intermediate and high complexity groups, respectively. Median survival was 23.1 (95% CI 19.0 to 27.2) vs. 22.0 (95% CI 17.6 to 26.3) vs. 17.9 months (95% CI 15.7 to 20.1), p = 0.043 in mainly high SCS, intermediate, and low SCS centres, respectively. In an age and deprivation adjusted model, compared to patients in the high SCS centres, patients in the low SCS group had an HR of 1.21 (95% CI 1.03 to 1.40) for death. Mainly high/intermediate SCS centres have significantly higher surgery rates and better survival at a population level. Centres that practice mainly low complexity surgery should change practice. This study provides support for the utilization of URS for patients with advanced OC.
Open AccessInvestigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study
We investigated URS and impact on survival in whole patient cohorts with AOC treated within gynaecological cancer centres that participated in the previously presented SOCQER 2 study. National cancer registry datasets were used to identify FIGO Stage 3,4 and unknown stage patients from 11 cancer centres that had previously participated in the SOCQER2 study. Patient outcomes’ association with surgical ethos were evaluated using logistic regression and Cox proportional hazards. Centres were classified into three groups based on their surgical complexity scores (SCS); those practicing mainly low complexity, (5/11 centres with >70% low SCS procedures, 759 patients), mainly intermediate (3/11, 35–50% low SCS, 356 patients), or mainly high complexity surgery (3/11, >35% high SCS, 356 patients). Surgery rates were 43.2% vs. 58.4% vs. 60.9%. across mainly low, intermediate and high SCS centres, respectively, p < 0.001. Combined surgery and chemotherapy rates were 39.2% vs. 51.8% vs. 38.3% p < 0.000 across mainly low, intermediate and high complexity groups, respectively. Median survival was 23.1 (95% CI 19.0 to 27.2) vs. 22.0 (95% CI 17.6 to 26.3) vs. 17.9 months (95% CI 15.7 to 20.1), p = 0.043 in mainly high SCS, intermediate, and low SCS centres, respectively. In an age and deprivation adjusted model, compared to patients in the high SCS centres, patients in the low SCS group had an HR of 1.21 (95% CI 1.03 to 1.40) for death. Mainly high/intermediate SCS centres have significantly higher surgery rates and better survival at a population level. Centres that practice mainly low complexity surgery should change practice. This study provides support for the utilization of URS for patients with advanced OC.
- 1 March 2021
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 258, 332-342
Options for triage and implications for colposcopists within European HPV-based cervical screening programmes
- 1 March 2021
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 258, 332-342
Options for triage and implications for colposcopists within European HPV-based cervical screening programmes
- Open Access
Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
Randomised controlled trials of ovarian cancer (OC) screening have not yet demonstrated an impact on disease mortality. Meanwhile, the screening data from clinical trials represents a rich resource to understand the performance of modalities used. We report here on incidence screening in the ultrasound arm of UKCTOCS. 44,799 of the 50,639 women who were randomised to annual screening with transvaginal ultrasound attended annual incidence screening between 28 April 2002 and 31 December 2011. Transvaginal ultrasound was used both as the first and the second line test. Participants were followed up through electronic health record linkage and postal questionnaires. Out of 280,534 annual incidence screens, 960 women underwent screen-positive surgery. 113 had ovarian/tubal cancer (80 invasive epithelial). Of the screen-detected invasive epithelial cancers, 37.5% (95% CI: 26.9–49.0) were Stage I/II. An additional 52 (50 invasive epithelial) were diagnosed within one year of their last screen. Of the 50 interval epithelial cancers, 6.0% (95% CI: 1.3–16.5) were Stage I/II. For detection of all ovarian/tubal cancers diagnosed within one year of screen, the sensitivity, specificity, and positive predictive values were 68.5% (95% CI: 60.8–75.5), 99.7% (95% CI: 99.7–99.7), and 11.8% (95% CI: 9.8–14) respectively. When the analysis was restricted to invasive epithelial cancers, sensitivity, specificity and positive predictive values were 61.5% (95% CI: 52.6–69.9); 99.7% (95% CI: 99.7–99.7) and 8.3% (95% CI: 6.7–10.3), with 12 surgeries per screen positive. The low sensitivity coupled with the advanced stage of interval cancers suggests that ultrasound scanning as the first line test might not be suitable for population screening for ovarian cancer. Trial registration: ISRCTN22488978. Registered on 6 April 2000.
Open AccessPerformance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
Randomised controlled trials of ovarian cancer (OC) screening have not yet demonstrated an impact on disease mortality. Meanwhile, the screening data from clinical trials represents a rich resource to understand the performance of modalities used. We report here on incidence screening in the ultrasound arm of UKCTOCS. 44,799 of the 50,639 women who were randomised to annual screening with transvaginal ultrasound attended annual incidence screening between 28 April 2002 and 31 December 2011. Transvaginal ultrasound was used both as the first and the second line test. Participants were followed up through electronic health record linkage and postal questionnaires. Out of 280,534 annual incidence screens, 960 women underwent screen-positive surgery. 113 had ovarian/tubal cancer (80 invasive epithelial). Of the screen-detected invasive epithelial cancers, 37.5% (95% CI: 26.9–49.0) were Stage I/II. An additional 52 (50 invasive epithelial) were diagnosed within one year of their last screen. Of the 50 interval epithelial cancers, 6.0% (95% CI: 1.3–16.5) were Stage I/II. For detection of all ovarian/tubal cancers diagnosed within one year of screen, the sensitivity, specificity, and positive predictive values were 68.5% (95% CI: 60.8–75.5), 99.7% (95% CI: 99.7–99.7), and 11.8% (95% CI: 9.8–14) respectively. When the analysis was restricted to invasive epithelial cancers, sensitivity, specificity and positive predictive values were 61.5% (95% CI: 52.6–69.9); 99.7% (95% CI: 99.7–99.7) and 8.3% (95% CI: 6.7–10.3), with 12 surgeries per screen positive. The low sensitivity coupled with the advanced stage of interval cancers suggests that ultrasound scanning as the first line test might not be suitable for population screening for ovarian cancer. Trial registration: ISRCTN22488978. Registered on 6 April 2000.
- 1 January 2021
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 256, 57-62
European consensus statement on essential colposcopy
- 1 January 2021
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 256, 57-62
European consensus statement on essential colposcopy
- 1 December 2020
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 255, 40-43
Using technology to harmonise treatment approaches in colposcopy in the face of a changing environment
- 1 December 2020
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 255, 40-43
Using technology to harmonise treatment approaches in colposcopy in the face of a changing environment
- Open Access
- 28 November 2020
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 128 (7) , 1226-1235
Introducing human papillomavirus (HPV) primary testing in the age of HPV vaccination: projected impact on colposcopy services in Wales
Objective: To determine the demand for colposcopy in the Cervical Screening Wales programme after the introduction of human papillomavirus (HPV) cervical screening, which coincided with the start of screening of women vaccinated against HPV types 16/18.Design: The study used a computational model that assigns screening and screening‐related colposcopy events to birth cohorts in individual calendar years.Setting: Cervical Screening Wales.Population: Women aged 25–64 years from birth cohorts 1953–2007.Methods and main outcome measures: We estimated the numbers of colposcopies and high‐grade cervical intraepithelial lesions (CIN2+) within Cervical Screening Wales in 2018–32, using official population projections for Wales and published estimates of the effects of HPV screening and vaccination.Results: Vaccination will reduce the number of colposcopies by 10% within the first 3–4 years after the national roll‐out of HPV screening, and by about 20% thereafter. The number of screening colposcopies is estimated to increase from 6100 in 2018 and peak at 8000 (+31%) in 2021, assuming current screening intervals are maintained. The numbers of CIN2+ lesions follow similar patterns, stabilising at around 1000 diagnoses per year by 2026, approximately 60% lower than at present. Extending the screening intervals to 5 years for all women shows similar trends but introduces peaks and troughs over the years.Conclusions: Vaccination will not fully prevent an increase in colposcopies and detected CIN2+ lesions during the first 2–3 years of HPV‐based screening but the numbers are expected to decrease substantially after 5–6 years.Tweetable HPV‐based cervical screening will initially increase colposcopy referral. In 6 years, this increase will be reversed, partly by HPV vaccination.
- 28 November 2020
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 128 (7) , 1226-1235
Open AccessIntroducing human papillomavirus (HPV) primary testing in the age of HPV vaccination: projected impact on colposcopy services in Wales
Objective: To determine the demand for colposcopy in the Cervical Screening Wales programme after the introduction of human papillomavirus (HPV) cervical screening, which coincided with the start of screening of women vaccinated against HPV types 16/18.Design: The study used a computational model that assigns screening and screening‐related colposcopy events to birth cohorts in individual calendar years.Setting: Cervical Screening Wales.Population: Women aged 25–64 years from birth cohorts 1953–2007.Methods and main outcome measures: We estimated the numbers of colposcopies and high‐grade cervical intraepithelial lesions (CIN2+) within Cervical Screening Wales in 2018–32, using official population projections for Wales and published estimates of the effects of HPV screening and vaccination.Results: Vaccination will reduce the number of colposcopies by 10% within the first 3–4 years after the national roll‐out of HPV screening, and by about 20% thereafter. The number of screening colposcopies is estimated to increase from 6100 in 2018 and peak at 8000 (+31%) in 2021, assuming current screening intervals are maintained. The numbers of CIN2+ lesions follow similar patterns, stabilising at around 1000 diagnoses per year by 2026, approximately 60% lower than at present. Extending the screening intervals to 5 years for all women shows similar trends but introduces peaks and troughs over the years.Conclusions: Vaccination will not fully prevent an increase in colposcopies and detected CIN2+ lesions during the first 2–3 years of HPV‐based screening but the numbers are expected to decrease substantially after 5–6 years.Tweetable HPV‐based cervical screening will initially increase colposcopy referral. In 6 years, this increase will be reversed, partly by HPV vaccination.
- Open Access
Fostering Prevention of Cervical Cancer by a Correct Diagnosis of Precursors: A Structured Case-Based Colposcopy Course in Finland, Norway and UK
High-quality colposcopy is essential in cervical cancer prevention. We performed a multicentre prospective interventional pilot-study, evaluating the effect of a six-hour case-based colposcopy course on short- and long-term learning of colposcopy-related knowledge, diagnostic accuracy levels and confidence. We recruited 213 colposcopists participating in three European Federation of Colposcopy (EFC) basic colposcopy courses (Finland, Norway, UK). The study consisted of three tests with identical content performed before, after and 2 months after the course, including ten colposcopic images, ten patient cases and scales for marking confidence in the answers. Outcome measures where mean scores in correct case-management, diagnosis (including high-grade lesion recognition), transformation-zone recognition and confidence in answers. Results were compared between the three tests and stratified according to experience. Mean test scores improved after the course for all participants. The increase was highest for beginners. Confidence in answers improved and the number of colposcopists showing high confidence with low scores decreased. A structured case-based course improves skills and confidence especially for inexperienced colposcopists; however, trainers should be aware of the risk of overconfidence. To complement theoretical training, further hands-on training including high-quality feedback is recommended. Conclusions drawn from long-term learning are limited due to the low participation in the follow-up test.
Open AccessFostering Prevention of Cervical Cancer by a Correct Diagnosis of Precursors: A Structured Case-Based Colposcopy Course in Finland, Norway and UK
High-quality colposcopy is essential in cervical cancer prevention. We performed a multicentre prospective interventional pilot-study, evaluating the effect of a six-hour case-based colposcopy course on short- and long-term learning of colposcopy-related knowledge, diagnostic accuracy levels and confidence. We recruited 213 colposcopists participating in three European Federation of Colposcopy (EFC) basic colposcopy courses (Finland, Norway, UK). The study consisted of three tests with identical content performed before, after and 2 months after the course, including ten colposcopic images, ten patient cases and scales for marking confidence in the answers. Outcome measures where mean scores in correct case-management, diagnosis (including high-grade lesion recognition), transformation-zone recognition and confidence in answers. Results were compared between the three tests and stratified according to experience. Mean test scores improved after the course for all participants. The increase was highest for beginners. Confidence in answers improved and the number of colposcopists showing high confidence with low scores decreased. A structured case-based course improves skills and confidence especially for inexperienced colposcopists; however, trainers should be aware of the risk of overconfidence. To complement theoretical training, further hands-on training including high-quality feedback is recommended. Conclusions drawn from long-term learning are limited due to the low participation in the follow-up test.
- Open Access
- 1 May 2018
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 224, 137-141
2017 update of the European Federation for Colposcopy (EFC) performance standards for the practice of colposcopy
- 1 May 2018
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 224, 137-141
Open Access2017 update of the European Federation for Colposcopy (EFC) performance standards for the practice of colposcopy
- Open Access
- 23 June 2015
- Published by Springer Nature
A trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT-G)
- 23 June 2015
- Published by Springer Nature
Open AccessA trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT-G)